| Anthony Pagano |
Anthony Pagano is currently the Chief Financial Officer & Executive Vice President at Genmab A since 2020. Prior to his current position, he worked as the Controller & Senior Director-Business Planning at NovaDel Pharma, Inc. from 2005 to 2007. Before that, he was a Manager at KPMG LLP from 1999 to 2005. Mr. Pagano holds an undergraduate degree from The College of New Jersey and an MBA from The Leonard N Stern School of Business. |
| Martine J. van Vugt |
Martine J. van Vugt is currently an Independent Director at Scandion Oncology A, a Director at Hollandbio, the Chief Strategy Officer & Executive Vice President at Genmab A, an Independent Member-Supervisory Board at TME Pharma NV, and a Member-Supervisory Board at Immagene BV. Dr. van Vugt holds a doctorate degree from the University of Utrecht and a graduate degree from Wageningen University. |
| Judith Klimovsky |
Judith Klimovsky is a professional who currently holds the position of Chief Development Officer & Executive VP at Genmab A since 2017. Prior to this, she worked as Senior Vice President & Head-Clinical Development at Novartis AG and Novartis Pharma AG from 2009 to 2017. She also worked as a Director at Bellicum Pharmaceuticals, Inc. from 2018 to 2024. Dr. Klimovsky holds a doctorate degree from the University of Buenos Aires School of Medicine. |
| Tahamtan Ahmadi |
Tahamtan Ahmadi is currently the Chief Medical Officer & Executive Vice President at Genmab A. Previously, he worked at Janssen-Cilag A as the Head of Experimental Medicine & Member. He holds a doctorate degree from the University of Freiburg and Universität zu Köln. |
| Anthony Mancini |
Anthony Mancini is currently the Chief Operating Officer & Executive Vice President at Genmab A since 2020. He holds an MBA from Clemson University and an undergraduate degree from the University of Ottawa. |
| Christopher Cozic |
Christopher Cozic is currently the Chief People Officer & Executive Vice President at Genmab A. Previously, he worked as the Director-Global Human Resources at Eisai Co., Ltd. and as the Vice President-Human Resources at Ipsen SA from 2014 to 2017. He completed his undergraduate degree at Quinnipiac University. |
| Martin Schultz |
Martin Schultz currently works at Genmab A, as Non-Independent Director from 2022. |
| Deirdre P. Connelly |
Deirdre P. Connelly is currently the Chairman at Genmab A since 2020. She is also an Independent Director at Macy's, Inc. since 2008, an Independent Director at Lincoln National Corp. since 2016, and a Director at Harvard University in the Public Health Policy Council. Ms. Connelly's former positions include being the President, Chief Executive Officer & Director at Human Genome Sciences, Inc. from 2012 to 2015. She was also a Director at Pharmaceutical Research & Manufacturers of America, an Executive Director-Global Marketing at Evista Industries, Inc., and a Director at Norwest Indiana, Inc. Additionally, she served as the President-US Operations at Eli Lilly & Co. from 2005 to 2009, the President-North American Pharmaceuticals at GSK Plc from 2009 to 2015, and the General Manager-Sales at Eli Lilly Export SA. She was also the President-North America Pharmaceuticals at Genelabs Technologies, Inc. from 2009 to 2015. Ms. Connelly obtained her undergraduate degree from Lycoming College in 1983. |
| Birgitte Stephensen |
Birgitte Stephensen is currently working as the Chief Legal Officer & Executive Vice President at Genmab A since 2002. She graduated from Danmarks Farmaceutiske Universitet. |
| Jan G. J. van de Winkel |
Jan G. J. van de Winkel is the founder and currently holds the position of President & Chief Executive Officer at Genmab A, a company founded in 1999. He is also currently serving as Chairman-Supervisory Board at Regenesance BV, Chairman-Supervisory Director at Hookipa Biotech AG, Chairman at HOOKIPA Pharma, Inc., Director at LEO Pharma A, Director at Leo Pharma, Inc., and Independent Director at Omega Alpha SPAC. In his former positions, Dr. van de Winkel served as Vice President & Scientific Director at Medarex, Inc. and Medarex Europe BV, Director at Forward Pharma A from 2014 to 2017, Director at Celdara Medical LLC, Member at BTF Pty Ltd., and Member-Supervisory Board at ISA Pharmaceuticals BV. Dr. van de Winkel's education includes undergraduate and graduate degrees from the University of Utrecht, as well as a graduate and doctorate degree from Radboud University Nijmegen. |
| Pernille Lyngvold Erenbjerg |
Pernille Lyngvold Erenbjerg is currently the Deputy Chairman at Millicom International Cellular SA and the Deputy Chairman at Genmab A. She is also the Chairman at KK Wind Solutions A, Chairman at Iver AB, Independent Non-Executive Director at RTL Group SA, Director at Det Kongelige Teater, Director at GlobalConnect AB, Director at Innargi A, and Director at GlobalConnect Oy. In her former positions, Ms. Erenbjerg served as the President & Chief Executive Officer at TDC Holding A from 2003 to 2018. She was also the Deputy Chairman at DFDS A from 2014 to 2018, Chairman at Viaplay Group AB from 2020 to 2023, and Independent Director at Nordea Bank AB from 2017 to 2018. Additionally, she held various director roles at Get AS, GlobalConnect A, and Royal Danish Theatre from 2011 to 2015. Prior to that, she worked as an Auditor at Arthur Andersen Kihlman Oy from 1987 to 2002 and as a Partner at Deloitte Touche Tohmatsu Ltd. from 2002 to 2003. She also served as the Executive Vice President at TDC Services A.Ms. Erenbjerg completed her undergraduate studies at Copenhagen Business School and obtained a graduate degree from the same institution in 1992. |
| Rolf K. Hoffmann |
Rolf K. Hoffmann is currently the Chairman of BPC Plasma, Inc. He is also an Independent Director at Sun Pharmaceutical Industries Ltd. and Genmab A. In addition, he holds director positions at IDT Biologika GmbH, World Anti-Doping Agency, NavBio AG, Trizell Ltd., Idt Biologika Corp., Semdor Pharma Group GmbH, and Dessau-Rosslau. Previously, he served as the Chief Executive Officer-Global Marketing at Lilly Deutschland GmbH and held various director and chairman positions at Biotest AG, EUSA Pharma, Inc., Trigemina, Inc., Copenhagen Capital A, Paratek Pharmaceuticals, Inc., Shield Therapeutics Plc, Ferring Holding, Inc., and Trizell Holding SA. He was also the Vice President-US Commercial Operations at Amgen, Inc. and the General Manager-Germany at Eli Lilly & Co. He has a graduate degree from Universität zu Köln, an MBA from The University of North Carolina at Chapel Hill, and a graduate degree from Deutsche Sporthochschule Köln. |
| Elizabeth G. O'Farrell |
Elizabeth G. O'Farrell is currently serving as the Chairman at PDL BioPharma, Inc. since 2020, as an Independent Director at Geron Corp. since 2019, as an Independent Director at LENSAR, Inc. since 2021, as an Independent Director at Genmab A since 2022, and as a Director at Karius, Inc. since 2023. In the past, Ms. O'Farrell held positions such as Chairman at Y.M.C.A. Foundation of Greater Indianapolis from 2014 to 2016, Chief Financial Officer & Executive Director at Eli Lilly Canada, Inc., Director at Washington Township Schools Foundation from 2003 to 2010, Independent Director at Inhibikase Therapeutics, Inc. from 2019 to 2022, Director at Keep Indianapolis Beautiful, Inc., Chief Procurement Officer at Eli Lilly & Co. from 2012 to 2017, Accountant at OfficeMax Contract, Inc., Auditor at Pricewaterhouse LLP, Auditor at Whipple & Co., and Manager at Somerset Financial Services LLC. Ms. O'Farrell also served as the Chief Financial Office and SVP-Policy & Finance at Lilly USA LLC. Ms. O'Farrell completed an MBA from Indiana University in 1987 and an undergraduate degree from Indiana University in 1986. |
| Paolo Augusto Paoletti |
Paolo Augusto Paoletti is currently serving as an Independent Director at Genmab A since 2015. He is also a Director at Biomed Ltd., a Non-Executive Director at Akamis Bio Ltd., and a Director at Grid Therapeutics LLC. In his former positions, Dr. Paoletti served as the Chairman & Chief Executive Officer at Kesios Therapeutics Ltd. from 2015 to 2017. He was also the Chief Executive Officer & Director at Gammadelta Therapeutics Ltd. and a Director at FORMA Therapeutics, Inc. Additionally, he held the role of Independent Non-Executive Director at Forma Therapeutics Holdings, Inc. from 2015 to 2021. Dr. Paoletti was a Non-Executive Director at NuCana Plc and Vice President-Oncology Research at Eli Lilly & Co. He also served as the President-Oncology Division at GSK Plc from 2013 to 2015 and as Vice President-Clinical Development at Lilly Oncology. Dr. Paoletti obtained a doctorate degree from the University of Pisa. |
